These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15148272)

  • 21. Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Hara T; Uemoto R; Sekine A; Mitsui Y; Masuda S; Yamagami H; Kurahashi K; Yoshida S; Otoda T; Yuasa T; Kuroda A; Ikeda Y; Endo I; Honda S; Yoshimoto K; Kondo A; Tamaki T; Matsumoto T; Matsuhisa M; Abe M; Aihara KI
    J Atheroscler Thromb; 2023 Aug; 30(8):871-883. PubMed ID: 36244745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study.
    Rau JC; Deans C; Hoffman MR; Thomas DB; Malcom GT; Zieske AW; Strong JP; Koch GG; Church FC
    Exp Mol Pathol; 2009 Dec; 87(3):178-83. PubMed ID: 19747479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased heparin cofactor II levels in women taking oral contraceptives.
    Toulon P; Bardin JM; Blumenfeld N
    Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
    Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Heparin cofactor II (HCII) activity and antigen assay and their significance in thrombotic diseases].
    Dai CW; Zhang GS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Sep; 24(9):452-4. PubMed ID: 14575585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.
    Sumitomo-Ueda Y; Aihara K; Ise T; Yoshida S; Ikeda Y; Uemoto R; Yagi S; Iwase T; Ishikawa K; Hirata Y; Akaike M; Sata M; Kato S; Matsumoto T
    Hypertension; 2010 Sep; 56(3):430-6. PubMed ID: 20660821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin cofactor II significance for the inhibition of thrombin at the injured vessel wall.
    Pasche B; Swedenborg J; Frebelius S; Olsson P
    Thromb Res; 1991 Jun; 62(5):409-19. PubMed ID: 1896960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome.
    Toulon P; Gandrille S; Remy P; Chadeuf G; Jouvin MH; Aiach M
    Nephron; 1992; 60(2):176-80. PubMed ID: 1553002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex.
    Han JH; Tollefsen DM
    Biochemistry; 1998 Mar; 37(9):3203-9. PubMed ID: 9485475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II.
    Porter JB; Young L; Mackie IJ; Marshall L; Machin SJ
    Br J Haematol; 1993 Mar; 83(3):459-65. PubMed ID: 8485052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.
    Aihara K; Azuma H; Akaike M; Ikeda Y; Sata M; Takamori N; Yagi S; Iwase T; Sumitomo Y; Kawano H; Yamada T; Fukuda T; Matsumoto T; Sekine K; Sato T; Nakamichi Y; Yamamoto Y; Yoshimura K; Watanabe T; Nakamura T; Oomizu A; Tsukada M; Hayashi H; Sudo T; Kato S; Matsumoto T
    J Clin Invest; 2007 Jun; 117(6):1514-26. PubMed ID: 17549254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carotid atherosclerosis and cardiovascular risk factors: a comparison of residents of a rural area of Okinawa with residents of a typical suburban area of Fukuoka, Japan.
    Tatsukawa M; Sawayama Y; Maeda N; Okada K; Furusyo N; Kashiwagi S; Hayashi J
    Atherosclerosis; 2004 Feb; 172(2):337-43. PubMed ID: 15019544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.
    Páramo JA; Orbe J; Beloqui O; Benito A; Colina I; Martinez-Vila E; Diez J
    Stroke; 2004 May; 35(5):1085-9. PubMed ID: 15017006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
    Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-2-macroglobulin and heparin cofactor II and the vulnerability of carotid atherosclerotic plaques: An iTRAQ-based analysis.
    Li J; Liu X; Xiang Y; Ding X; Wang T; Liu Y; Yin M; Tan C; Deng F; Chen L
    Biochem Biophys Res Commun; 2017 Feb; 483(3):964-971. PubMed ID: 28087279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Associations between carotid intima-media thickness, plaque and cardiovascular risk factors].
    Lee YH; Cui LH; Shin MH; Kweon SS; Park KS; Jeong SK; Chung EK; Choi JS
    J Prev Med Public Health; 2006 Nov; 39(6):477-84. PubMed ID: 17168200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin cofactor II deficiency in patients infected with the human immunodeficiency virus.
    Toulon P; Lamine M; Ledjev I; Guez T; Holleman ME; Sereni D; Sicard D
    Thromb Haemost; 1993 Nov; 70(5):730-5. PubMed ID: 8128426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apo-lipoprotein profile in subjects with extracranial carotid atherosclerosis.
    Barbagallo CM; Averna MR; Novo S; Cavera G; Noto D; Liquori M; Spano L; Notarbartolo A
    Int Angiol; 1994 Sep; 13(3):223-8. PubMed ID: 7822898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
    Halldórsdóttir AM; Zhang L; Tollefsen DM
    Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis.
    Toulon P; Vitoux JF; Fiessinger JN; Sicard D; Aiach M
    Blood Coagul Fibrinolysis; 1991 Jun; 2(3):435-9. PubMed ID: 1718466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.